Simons F E
Children's Hospital, Winnipeg, Manitoba, Canada R3A 1S1.
Postgrad Med. 1999 Dec;106(7 Suppl):7-11. doi: 10.3810/pgm.12.1999.suppl2.7.
Histamine, a pivotal mediator of inflammation, has been the target of therapeutic intervention in allergic disorders for the better part of the past century. During this time, the benefit-to-risk profiles of H1-receptor antagonists have improved. This review explores the pharmacologic properties of these agents, their roles in treating allergic disorders, their safety, and the avenues of future inquiry that might further define their therapeutic possibilities.
组胺作为炎症的关键介质，在过去大半个世纪一直是过敏性疾病治疗干预的靶点。在此期间，H1受体拮抗剂的效益风险比有所改善。本综述探讨了这些药物的药理学特性、它们在治疗过敏性疾病中的作用、安全性以及未来可能进一步明确其治疗潜力的研究方向。
